Options Trading News

Drug Progresses to Final Stage of Testing

Lexicon Pharmaceuticals reported positive data for its drug that treats carcinoid tumors. It's now moving from Phase 2 trials to Phase 3 trials, sending LXRX higher by 13 percent in the premarket.

Infosys Sees Weaker Profit

Infosys now expect full-year earnings of $2.97 a share, versus its previous forecast of $3.03.The outsourcing company also failed to raise it revenue guidance as analysts had hoped. INFY drops 5 percent in early trading.

J.B. Hunt Revenue Beats Expectations

J.B. Hunt Transport Services had third-quarter revenue of $1.30 billion, beating the $1.28 billion estimate. Profit missed expectations, but investors are focusing on that strong top-line number and sending JBHT higher by about 5 percent in the premarket.

Weak PC Market Drags on AMD

Advanced Micro Devices preannounced that third-quarter revenue fell by about 10 percent. It had previously forecast a decline of no more than 4 percent. Management cited a weakening PC market, and AMD is lower by 9 percent in the pre.